Vaccines-2013 - OMICS Group

Recommendations

Info

Nikolai Petrovsky, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAStrategies for generation of broadly cross-neutralising anti-influenza vaccine responsesNikolai PetrovskyFlinders Medical Centre and Vaxine Pty Ltd., AustraliaIncreasing evidence points to the importance of broadly cross-neutralizing anti-influenza responses in providing protectionagainst pandemic strains but current seasonal influenza vaccines are poorly effective at generating such responses. Ourgroup has been exploring techniques to enhance broadly cross-neutralizing anti-influenza responses that involve use of novelrecombinant influenza antigens adjuvants (FluBlok TM , Protein Sciences Corporation) together with novel adjuvant technology(Advax TM , Vaxine Pty Ltd). This novel approach has already been advanced to the clinic and has shown promising results in itsability to modulate both anti-influenza B- and T-cell responses, in the process inducing changes in plasmablast and memoryB-cell frequency, immunoglobulin subtype and B-cell receptor usage. The significance of these changes is still being explored inanimal challenge models, but suggests that these new approaches to influenza vaccine design may one day enable production of auniversal influenza vaccine that no longer needs to be administered on an annual basis to at risk individuals. Such vaccines couldbe major life savers in the event of a future pandemic involving H5N1, H7N9 or some other new serotype of avian influenza.BiographyNikolai Petrovsky MBBS, FRACP, Ph.D. is an active hospital clinician, research professor at Flinders Medical Centre, Adelaide Australia andresearch director of Vaxine, an Australian vaccine development company. He is Secretary-General of the International Immunomics Society andhas received major funding from the US National Institutes of Health to develop novel biodefense vaccines and adjuvants. He has won prestigiousawards including the AMP Innovation Award at the 2009 Telstra Business Awards and an Ernst & Young Entrepreneur of the Year in 2010. He hastaken four vaccines to the clinic and has authored over 100 scientifi c papers and book chapters.nikolai.petrovsky@flinders.edu.auJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 44
Hong Xin, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USANew strategies to present an anti-candidiasis synthetic glycopeptide vaccine acceptable forhuman useHong Xin, Jonathan Cartmell, David R. Bundle and Jim E. CutlerLSUHSC & Children's Hospital Research Institute, USABackground: Our research on pathogenesis of experimental disseminated candidiasis led to the discovery that antibodies specificfor Candida albicans cell surface β-1, 2-mannotriose [b-(Man)3] protect mice against the disease. Use of a 14 mer peptide Fba,which derived from the N-terminal portion of the C. albicans cell surface protein fructose-bisphosphate aldolase, as the carrierfor the glycan has resulted in a novel synthetic glycopeptide vaccine b-(Man)3-Fba. This conjugate uniquely induces protectiveresponses against both the glycan and peptide carrier parts of the vaccine in a mouse model of human disseminated candidiasis.Current work: We have isolated monoclonal antibodies (MAbs) specific for the Fba peptide. Use of these MAbs in flow cytometricand confocal microscopic analyses provide evidence that the peptide is expressed on the fungal cell surface during growth as yeastand hyphal forms. Furthermore, one of the MAbs given passively to naïve mice protects the animals against candidiasis. Weconclude that the b-(Man)3-Fba vaccine protects mice by inducing protective antibodies against both the glycan and peptideparts of the vaccine conjugate. We have now modified the b-(Man)3-Fba conjugate by coupling it to tetanus toxoid (TT) in orderto improve immunogenicity and allow for use of an adjuvant suitable for human use. b-(Man)3-Fba-TT was administered alone,or as either a mixture made with alum or monophosphoryl lipid A (MPL) adjuvants by subcutaneous (s.c.) injection in miceon days 1, 21 and 62. Mice that received the conjugate vaccine prepared in either adjuvant responded as expected by makingrobust antibody responses. Surprisingly, mice that received the b-(Man)3-Fba-TT without adjuvant also responded well. All threegroups of mice also showed protection against a lethal challenge with C. albicans as evidenced by increased median survival timesand reduced kidney fungal burden as compared to control groups that received only adjuvants or DPBS buffer prior to challenge.To confirm that induced antibodies were protective, sera from mice immunized against the b-(Man)3-Fba-TT conjugate werefound to transfer protection against disseminated candidiasis to naïve mice, whereas C. albicans-adsorbed immune sera did not.Conclusion: We conclude that tetanus toxiod is a suitable secondary carrier for the glycopeptide conjugate as it induces robustantibody responses and protective immunity administered with or without adjuvants that may be suitable for human use.hxin@chnola-research.orgJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 45
Page 1 and 2: 111 th OMICS Group ConferenceJuly 2
Page 3 and 4: Medical SciencesISSNAddiction Resea
Page 5 and 6: Impact Factors (IF) and Index Coper
Page 7 and 8: 111 th OMICS Group Conference3 rd I
Page 9 and 10: Journal of Clinical & Cellular Immu
Page 15 and 16: Clinical Microbiology-2013OMICS Gro
Page 17 and 18: Immunology Summit-2013OMICS Group i
Page 19 and 20: Probiotics-2013OMICS Group is organ
Page 21 and 22: Virology-2013OMICS Group is organiz
Page 25 and 26: Because of heightened awareness of
Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
Page 39 and 40: Robert E. Sievers et al., J Vaccine
Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43: Campbell Bunce, J Vaccines Vaccin 2
Page 47 and 48: Diane Longo et al., J Vaccines Vacc
Page 49 and 50: Track 33: Novel Approaches in Desig
Page 51 and 52: Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96:
111 th OMICS Group Conference3 rd I
Page 97 and 98:
Regina Heidenreich et al., J Vaccin
Page 99 and 100:
Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102:
Zafer Kurugol et al., J Vaccines Va
Page 103 and 104:
Ates Kara et al., J Vaccines Vaccin
Page 105 and 106:
Yurong Tan et al., J Vaccines Vacci
Page 107 and 108:
Deryabin P.N. et al., J Vaccines Va
Page 109 and 110:
Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112:
Byung Chul Kim et al., J Vaccines V
Page 113 and 114:
STS. Chitradevi et al., J Vaccines
Page 115 and 116:
Yan Liang et al., J Vaccines Vaccin
Page 117 and 118:
Page 119 and 120:
Afshineh Latifynia et al., J Vaccin
Page 121 and 122:
Hemanta Koley et al., J Vaccines Va
Page 123 and 124:
Aleksandar Masic et al., J Vaccines
Page 125 and 126:
Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128:
Oladipo Aina et al., J Vaccines Vac
Page 129 and 130:
Aiswariya Chidambaram, J Vaccines V
Page 131 and 132:
Birhanu Hurisa et al., J Vaccines V
Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
Page 135 and 136:
Mathan Periasamy et al., J Vaccines
Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142:
Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148:
Belachew Etana et al., J Vaccines V
Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?